Literature DB >> 76017

Transmissible agent in non-A, non-B hepatitis.

H J Alter, R H Purcell, P V Holland, H Popper.   

Abstract

Plasma or serum from 4 patients with acute or chronic non-A, non-B post-transfusion hepatitis (P.T.H.) and from a blood-donor implicated in two cases of P.T.H. was inoculated into 5 chimpanzees. Biochemical and histological evidence of hepatitis developed in these 5 chimpanzees but not in a control animal. The mean incubation period in the chimpanzees was 13.4 weeks, compared with 7.7 weeks in the 4 patients with P.T.H. The peak alanine aminotransferase (A.L.T.) levels in the 5 chimpanzees were 265, 212, 219, 70, and 62 I.U./l. Histological changes ranged from mild to conspicuous hepatitis and generally correlated with the degree of A.L.T. elevation. There was no evidence of clinical disease and all animals went on to biochemical and histological recovery. There was no serological evidence of type A or type B hepatitis. Hepatitis was transmitted by serum derived from patients with chronic as well as acute hepatitis, strongly suggesting a chronic carrier state for the agent responsible for non-A, non-B hepatitis. Non-A, non-B hepatitis thus seems to be due to a transmissible agent which can persist and remain infectious for long periods.

Entities:  

Mesh:

Year:  1978        PMID: 76017     DOI: 10.1016/s0140-6736(78)90131-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  65 in total

1.  A transgenic mouse model of steatosis and hepatocellular carcinoma associated with chronic hepatitis C virus infection in humans.

Authors:  S M Lemon; H Lerat; S A Weinman; M Honda
Journal:  Trans Am Clin Climatol Assoc       Date:  2000

2.  Hypervariable region 1 sequence stability during hepatitis C virus replication in chimpanzees.

Authors:  S C Ray; Q Mao; R E Lanford; S Bassett; O Laeyendecker; Y M Wang; D L Thomas
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

Review 3.  Viruses and human cancer: from detection to causality.

Authors:  Ronit Sarid; Shou-Jiang Gao
Journal:  Cancer Lett       Date:  2010-10-23       Impact factor: 8.679

4.  Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity.

Authors:  A J Weiner; X Paliard; M J Selby; A Medina-Selby; D Coit; S Nguyen; J Kansopon; C L Arian; P Ng; J Tucker; C T Lee; N K Polakos; J Han; S Wong; H H Lu; S Rosenberg; K M Brasky; D Chien; G Kuo; M Houghton
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 5.  Hepatology.

Authors:  P M Harrison; J Y Lau; R Williams
Journal:  Postgrad Med J       Date:  1991-08       Impact factor: 2.401

6.  Immune response to purified non-A, non-B hepatitis-related antigen demonstrated by leukocyte migration inhibition in patients recovering from the infection.

Authors:  A Nicole; O Spertini; D Lavanchy; P C Frei
Journal:  Infection       Date:  1986 Jan-Feb       Impact factor: 3.553

Review 7.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

Review 8.  The hazards of blood transfusion in historical perspective.

Authors:  Harvey J Alter; Harvey G Klein
Journal:  Blood       Date:  2008-10-01       Impact factor: 22.113

Review 9.  Mortality and morbidity among military personnel and civilians during the 1930s and World War II from transmission of hepatitis during yellow fever vaccination: systematic review.

Authors:  Roger E Thomas; Diane L Lorenzetti; Wendy Spragins
Journal:  Am J Public Health       Date:  2013-01-17       Impact factor: 9.308

10.  Human monoclonal antibodies for the immunological characterization of a highly conserved protein domain of the hepatitis C virus glycoprotein E1.

Authors:  K Siemoneit; M da S Cardoso; K Koerner; A Wölpl; B Kubanek
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.